Antiviral Agents Bulletin - October 1997 U.S. Patents Section
Antiviral Agents Bulletin - October 1997 U.S. Patents Section
U.S. Patents
Each month the Antiviral Agents Bulletin presents abstracts of recently issued antiviral and virus-related U.S. patents. Patents are listed in numerical order. The abstract and major claim are generally presented as officially issued by the Patent and Trademark Office. Abstracts, claims, graphics and gene sequences may be deleted or edited for clarity.
Full copies of U.S. patents may be requested through your in-house library, local research libraries, commercial document delivery services, or from the Patent Office itself. Nearly every state in the U.S. has one or more patent depository libraries with copies of all U.S. patents, patent databases, and search assistance available.
**************
Method for Making Intermediates Useful in the Synthesis of Retroviral Protease Inhibitors
Assignee: G.D. Searle & Co.
Patent No.: 5,648,511
Inventors: Ng, J.S.; Przybyla, C.A.; Mueller, R.A.; Vazquez, M.L.; Getman, D.P.; DeCrescenzo, G.A.; Bertenshaw, D.E.; Heintz, R.M.; Zhang, S.; Liu, C.; Laneman, S.A.
Abstract:
A synthesis is described for intermediates which are readily amenable to the large scale preparation of hydroxyethylurea-based chiral HIV protease inhibitors. The method includes forming a diastereoselective epoxide or cyanohydrin from a chiral alpha amino aldehyde.
Claim:
A method of diastereoselectively preparing a chiral cyanohydrin compound of formula:
wherein P1 and P2 are each independently an acyl, aralkyl, alkenyl, silyl, aralkoxycarbonyl, alkoxycarbonyl or cycloalkenylalkyl radical; or P1, P2, and nitrogen atom to which they are bonded form a heterocyclic ring system containing said nitrogen atom as a ring member; and R1 is an alkyl, aryl, cycloalkyl, cycloalkylalkyl or aralkyl radical, each of which is optionally substituted with alkyl, halo, NO2, OR9, or SR9 radicals, wherein R9 is hydrogen or an alkyl radical; said method comprising the steps of diastereoselectively forming said chiral cyanohydrin compound from a chiral aldehyde of the formula:
by reacting the chiral aldehyde with a cyanide salt.
Recombinant Antibody Cytokine Fusion Proteins
Assignee: Unassigned or Assigned to Individuals
Patent No.: 5,650,150
Inventor: Gillies, S.D.
Abstract:
Immunoconjugates for the selective delivery of a cytokine to a target cell are disclosed. The fusion proteins are comprised of an immunoglobulin heavy chain having a specificity for the target cell, such as a cancer or virus-infected cell, and a cytokine, such as lymphotoxin, tumor necrosis factor alpha, interleukin-2, or granulocyte-macrophage colony stimulating factor, joined via its amino terminal amino acid to the carboxy-terminus of the immunoglobulin. Nucleic acid sequences encoding these fusion proteins and methods of their preparation by genetic engineering techniques are also disclosed.
Recombinant MarekÕs Disease Virus and Vaccine
Assignee: Research Found. for Microbial Diseases
Patent No.: 5,650,153
Inventors: Ishikawa, T.; Manabe, S.; Mori, C.; Takamizawa, A.; Yoshida, I.; Osame, J.; Takaku, K.; Fukai, K.
Abstract:
There is provided a recombinant MarekÕs disease virus comprising the genomic DNA of an attenuated MarekÕs disease virus and a foreign gene from another source. The present recombinant virus can advantageously be used as an active ingredient for a multifunctional live vaccine, exhibiting not only the antigenicity and immunogenicity of the MarekÕs disease virus but also the properties ascribed to the foreign gene. Since the suitable host cell for the recombinant virus of the present invention is an avian cell which is available in a large quantity and not expensive, the recombinant virus of the present invention can be produced efficiently at low cost on a commercial scale.
Method and Composition for Treating Hepatitis B
Assignee: DAWA Inc.
Patent No.: 5,650,167
Inventor: Allison, A.C.
Claim:
A method of inhibiting hepatitis B infection in a mammalian subject, comprising administering to the subject a therapeutically effective amount of a compound having the formula:
wherein R1 is selected from the group consisting of H and lower alkanoyl, and R2 is separately selected from the group consisting of H and lower alkyl.
Expression of Hepatitis B S and PreS2 Proteins in Pichia pastoris
Assignee: Research Corporation Technologies, Inc.
Patent No.: 5,650,296
Inventor: Thill, G.P.
Claim:
A process for the production of antigenic HBV particles from a Pichia pastoris strain consisting essentially of S and preS2 proteins which comprises: (a) transforming said Pichia pastoris strain with a first expression cassette containing a structural gene for a hepatitis B virus S protein operably linked to a 5' regulatory region and a 3' termination sequence obtainable from Pichia pastoris; and (b) transforming said Pichia pastoris strain with a second expression cassette containing a structural gene for the hepatitis B virus preS2 protein operably linked to a 5' regulatory region and a 3' termination sequence obtainable from Pichia pastoris; and (c) culturing the resulting transformed Pichia pastoris strain under suitable conditions to obtain the production of said HBV particles.
Recombinant Nucleic Acids for Inhibiting HIV Gene Expression
Assignee: University of Michigan
Patent No.: 5,650,306
Inventors: Nabel, G.J.; Yang, Z.-Y.; Liu, J.; Woffendin, C.
Abstract:
This invention provides recombinant nucleic acid molecules for enhanced expression of genes that inhibit HIV gene expression. Cells transfected with these recombinant nucleic acids exhibit prolonged cell life. This invention also provides methods of treating individuals infected with HIV by introducing into them the transfected cells of this invention.
Claim:
A recombinant nucleic acid molecule, comprising an expression control sequence and a TAR sequence, operatively linked to a negative transdominant mutant gene, wherein the negative transdominant mutant gene is a mutant of rev.
Viral vectors
Assignee: University of California
Patent No.: 5,650,309
Inventors: Wong-Staal, F.; Mamounas, M.; Poeschla, E.M.; Kraus, G.; Leavitt, M.
Abstract:
Vectors are provided which stably transduce cells, rendering the cells resistant to a target virus. The vectors are amplified upon infection of the cell by a target virus, and spread throughout an infected host in response to infection by the target virus.
Claim:
A vector comprising biologically active nucleic acid sequences from a first and second virus, wherein said nucleic acid sequences of said first virus comprise cis-active AAV nucleic acids for host cell chromosomal integration, said nucleic acid sequences of said second virus comprise a replication defective, rescuable retroviral genome, and wherein said nucleic acid sequences of said second virus also encodes an anti-viral agent operably linked to an expression control sequence.
Process and Culture Medium for the Production of Cells Infected by a Multiple Sclerosis-Associated Virus
Assignee: Bio Merieux
Patent No.: 5,650,318
Inventors: Perron, H.; Seigneurin, J.-M.
Abstract:
Process for in vitro production of a culture or cell line infected by a viral strain associated with multiple sclerosis (MS), according to which a body sample is taken from an individual suffering from MS, said sample is cultivated in a culture medium which promotes the growth of infected cells to obtain a culture of primary infected cells, and a sample of the culture of primary cells or of a subculture of the latter is cultivated in series, that is to say by successive passages, in said culture medium to obtain the culture or cell line infected by a virus associated with MS, which comprises a procedure in which the culture medium also contains a beta anti-interferon antibody or an antibody which is directed against an antigenically close molecule, the antibody playing an inhibiting role in viral expression and allowing long-lasting expression and propagation of the viral strain in the culture or cell line.
Human Monoclonal Antibody to Glycoprotein gpIII of Varicella Zoster Virus
Assignee: Teijin Ltd.
Patent No.: 5,650,319
Inventors: Masuho, Y.; Sugano, T.; Tomiyama, T.; Sasaki, S.; Kimura, T.; Kawamura, T.; Matsumoto, Y.
Abstract:
The human monoclonal antibody to the glycoprotein gpIII of varicella zoster virus (VZV), and hybridoma producing same, are provided. The hybridoma is obtained by immunizing human lymphocytes with gpIII antigen in the presence of a mitogen, and selecting a monoclonal antibody which reacts with a cell monolayer ELISA plate but substantially does not react with a cell homogenate ELISA plate.
Claim:
A human monoclonal antibody specific for glycoprotein gpIII of varicella zoster virus (VZV) having the following properties: (1) inhibits cell-to-cell infection of VZV at a concentration of 10 µg/ml; and (2) has VZV neutralizing activity as high as 1700 to 14000 times that of normal human serum immunoglobulin.
HIV Protease Inhibitors Useful for the Treatment of AIDS
Assignee: Merck & Co., Inc.
Patent No.: 5,650,412
Inventors: Kim, B.M.; Vacca, J.P.
Abstract:
Compounds of formula [not shown] are HIV protease inhibitors. These compounds are useful in the prevention or treatment of infection by HIV and in the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
Claim:
or a pharmaceutically acceptable salt thereof.
Thiadiazoles and Their Use as Antipicornaviral Agents
Assignee: Sanofi, S.A.
Patent No.: 5,650,419
Inventors: Aldous, D.J.; Bailey, T.R.; Diana, G.D.; Nitz, T.J.
Claim:
A compound of formula:
wherein: Thi is thiadiazolyl or thiadiazolyl substituted with alkoxy, fluoromethyl, difluoromethyl, trifluoromethyl, 1,1-difluoroethyl, halo, alkyl, cycloalkyl, hydroxyalkyl, or alkoxyalkyl; Y is an alkylene bridge of 3-9 carbon atoms; R1 and R2 are each independently chosen from hydrogen, halo, alkyl, alkenyl, amino, alkylthio, hydroxy, hydroxyalkyl, alkoxyalkyl, alkylthioalkyl, alkylsulfinyl alkyl, alkylsulfonylalkyl, alkoxy, nitro, carboxy, alkoxycarbonyl, dialkylaminoalkyl, alkylaminoalkyl, aminoalkyl, difluoromethyl, trifluoromethyl, or cyano; R3 is alkoxycarbonyl, alkyltetrazolyl, phenyl, or...[structural description truncated].
Method of Assaying CD4 Glycoproteins by Using Certain Azo Dyes
Assignee: U.S. Dept. of Health & Human Serv./NIH
Patent No.: 5,650,441
Inventors: Aszalos, A.; Weaver, J.C.; Pine, P.S.
Abstract:
Antiviral compositions useful for the inhibition of HIV include various azo dye compounds which have the ability of inhibiting the binding of HIV rgp120 to CD4 cells on peripheral blood lymphocytes and affecting HIV replication. Also disclosed are methods for treating HIV viral infections with these compositions.
Claim:
A method of detecting the presence or absence of CD4 glycoprotein in a sample, which method comprises contacting said sample in vitro with an azo dye derivative selected from the group consisting of:
[and numerous other azo dye structures not shown] and detecting whether any of said azo dye derivative bound to said sample.
Polypeptide Inhibitor of the Replication of HSV
Assignee: British Technology Group Ltd.
Patent No.: 5,650,488
Inventor: OÕHare, P.F.
Abstract:
A polypeptide which inhibits the replication of Herpes Simplex Virus. The polypeptide contains the amino acid sequence 360-367 of the Herpes Simplex Virus protein Vmw 65 as shown in Sequence I.D. No. 1 [not shown].
Antiviral Phosphonomethoxyalkylene Purine and Pyrimidine Derivatives
Assignee: Institute of Organic Chemistry and Biochemistry of the Academy of Sciences of the Czech Republic; Rega Stichting V.Z.W.
Patent No.: 5,650,510
Inventors: Webb, RW.; Bronson, J.J.; Martin, J.C.
Claim:
Formula I:
wherein B is a base selected from the group consisting of xanthine, hypoxanthine, 8-bromoguanine, 8-chloroguanine, 8-aminoguanine, 8-hydrazinoguanine, 8-hydroxyguanine, 8-methylguanine, 8-thioguanine, 2-aminopurine, 2,6-diaminopurine, and 2-amino-6-methoxyethoxypurine; alk1 is C1-4 alkylene; alk2 is independently selected from a chemical bond and C1-4 alkylene; alk3 is a chemical bond; Q and R2 are hydrogen; R1 is independently selected from hydrogen and C1-4 alkyl and wherein one of R1 or alk2 are C1-4 alkyl or C1-4 alkylene respectively; R3 and R4 are independently selected from hydrogen, C1-6 alkyl, phenyl, and phenyl-C1-4-alkylene; and the corresponding salts, and solvates thereof; provided, however, that when B is 2-amino-6-methoxyethoxypurine then R3 and R4 are ethyl, alk2 is a bond, R1 is H and alk1-C(R1)(alk2Q)-alk3 is 1,3 propylene or 1,4 butylene.
Lymphocytes or Their Lytics
Assignee: Unassigned or Assigned to Individuals
Patent No.: 5,651,970
Inventor: Allen, A.D.
Abstract:
Methods for treating and inhibiting disease and symptoms associated with the human immunodeficiency virus (HIV) are provided. The method includes transforming the human immunodeficiency virus (HIV) infection into a nonserious disease through the infusion of monoclonal antibodies directed against particular antigens on anti-self, anti-CD4 cytotoxic T-lymphocytes.
Claim:
A method for treating a patient having suppressed immune function resulting from human immunodeficiency virus infection in order to elevate the number of CD4+ cells in said patient, comprising the steps of: (a) infusing a dose of a monoclonal antibody selected from the group consisting of antibodies which specifically bind to ICAM-1, ICAM-2, and ICAM-3, said dose being between about 0.1-1.0 milligrams of said monoclonal antibody per kilogram of the patientÕs weight; and (b) repeating said infusion as necessary.
Use of Recombinant Swine Poxvirus as a Live Vaccine Vector
Assignee: University of Florida
Patent No.: 5,651,972
Inventors: Moyer, R.W.; Vinuela, E.; Gibbs, E.P.
Abstract:
The present invention provides a recombinant swinepox virus vector containing a heterologous nucleotide sequence encoding a protein from a selected pathogen inserted into, or replacing, all or a portion of a swinepox virus gene, which gene is not essential to replication of the virus in a host cell. Also provided is a recombinant SPV vector into which a pseudorabies antigen is inserted within the TK gene, which is useful in diagnostic, therapeutic, and prophylactic compositions.
Claim:
A recombinant vector comprising a swine poxvirus comprising a heterologous nucleotide sequence inserted into, or replacing all or a portion of a swine poxvirus gene or nucleic acid sequence, which gene or nucleic acid sequence is not essential to replication of the virus in a host cell, wherein said non-essential gene or nucleic acid sequence is selected from a gene or nucleic acid sequence present in the HindIII C fragment.
Recombinant Feline Herpesvirus Vaccine
Assignee: Akzo Nobel N.V.
Patent No.: 5,652,119
Inventors: Willemse, M.J.; Sondermeijer, P.J.
Abstract:
The present invention is concerned with a feline herpesvirus (FHV) mutant comprising a heterologous gene introduced into an insertion-region of the FHV genome. The invention also relates to a vector vaccine comprising such an FHV mutant which expresses a heterologous polypeptide derived from a feline pathogen and induces an adequate immune response in an inoculated host against both FHV and the feline pathogen.
Complementary DNA Encoding the Macrophage Inflammatory Protein-1alpha (MIP-1a)/Rantes Receptor
Assignee: U.S. Dept. of Health & Human Serv./NIH
Patent No.: 5,652,133
Inventor: Murphy, P.M.
Abstract:
This invention provides for the cloning and expression of the human Macrophage Inflammatory Protein-1alpha (MIP-1a)/RANTES Receptor. This receptor binds two cytokines MIP-1a and RANTES which are pro-inflammatory cytokines. The receptor is useful for assaying the levels of these cytokines in biological specimens. These cytokines play key roles in the inflammatory processes afflicting man.
Human Neutralizing Monoclonal Antibodies to Human Immunodeficiency Virus
Assignee: The Scripps Research Institute
Patent No.: 5,652,138
Inventors: Burton, D.R.; Barbas, C.F.; Lerner, R.A.
Abstract:
The present invention describes human monoclonal antibodies which immunoreact with and neutralize human immunodeficiency virus (HIV). Also disclosed are immunotherapeutic and diagnostic methods of using the monoclonal antibodies, as well as cell line for producing the monoclonal antibodies.
Claim:
A human monoclonal antibody that immunoreacts with human immunodeficiency virus (HIV) glycoprotein gp120, neutralizes HIV, and is produced by the cell line designated MT12 having A.T.C.C. Accession Number 69079.
YC1 Gene
Assignee: Dana-Farber Cancer Institute
Patent No.: 5,652,144
Inventors: Lu, Y.; Haseltine, W.A.
Abstract:
Isolated and purified YC1 genes and proteins are disclosed. The protein binds to a site in the HIV-LTR, the NRE-1 site, and can inhibit the expression of a gene operably linked to the HIV-1 LTR. The use of the protein and gene are discussed. Repressible and inducible expression systems using the YC1 gene are also disclosed.
Adenosine Diphosphoribose Polymerase Binding Nitroso Aromatic Compound Useful as Retroviral Inactivating Agents, Anti-Retroviral Agents and Anti-Tumor Agents
Assignee: Octamer, Inc.
Patent No.: 5,652,260
Inventors: Kun, E.; Mendeleyev, J.; Rice, W.C.
Abstract:
The subject invention provides for novel compounds for inactivating viruses. These compounds include 6-nitroso-1,2-benzopyrone, 3-nitrosobenzamide, 5-nitroso-1(2H)-isoquinolinone, 7-nitroso-1(2H)-isoquinolinone, 8-nitroso-1(2H)-isoquinolinone. The invention also provides for compositions containing one or more of the compounds, and for methods of treating viral infections, cancer, infectious virus concentration with compounds and compositions.
Claim:
A method of inactivating a virus having a Zn+2 finger nucleocapsid protein, said method comprising administering an effective amount of a Zn+2 finger destabilizing compound wherein said compound is selected from compounds having the formula:
wherein R1, R2, R3, R4, R5 and R6 are selected from the group consisting of hydrogen and nitroso, and only one of R1, R2, R3, R4, R5 and R6 is a nitroso group, a compound having the formula:
wherein R1, R2, and R3 are selected from the group consisting of hydrogen and nitroso, and only one of R1, R2, and R3 is a nitroso group, and a a compound having the formula:
wherein R1, R2, R3, R4, and R5 are selected from the group consisting of hydrogen and nitroso, and only one of R1, R2, R3, R4, and R5 is a nitroso group.
gC1q Receptor, HIV-1 gp120 Region Binding Thereto, and Related Peptides and Targeting Antibodies
Assignee: Tanox Biosystems, Inc.
Patent No.: 5,652,333
Inventors: Fung, M.S.; Sun, B.; Sun, C.R.; Kim, Y.W.; Yu, L.
Abstract:
Disclosed are immunogens and peptides based on the binding site of gC1q-R for HIV-1 gp120 and immunogens and peptides based on the binding site of HIV-1 gp120 for gC1q-R. The sequence of the gC1q-R binding site for gp120 is shown in Seq. I.D. No. 2 [not shown]. The sequence of the HIV-1 gp120 binding site for gC1q-R is shown in Seq. I.D. No. 3 [not shown] Also disclosed are antibodies and binding molecules to all such immunogens and peptides, and inducing the endogenous production of such antibodies.
Heterofunctional Cellular Immunological Reagents, Vaccines Containing Same and Methods for the Use of Same
Assignee: CEL-SCI Corp.
Patent No.: 5,652,342
Inventors: Zimmerman, D.H.; Elliott, D.A.
Abstract:
The present invention relates to a heterofunctional cellular immunological reagent comprising at least two T cell specific binding ligands covalently linked together, wherein one of the T cell specific binding ligands binds to a specific class or subclass of T cells and another of the T cell specific binding ligands is an antigen associated with disease or a causative agent of disease, or epitope thereof. The present invention also relates to vaccines containing the heterofunctional cellular immunological reagents and methods for the use of the same.
Claim:
A heterofunctional cellular immunological product comprising at least two T cell specific binding ligands covalently linked together, wherein the T cell specific binding ligands are derived from different molecules, and wherein one of said T cell specific binding ligands is a peptide which binds to a specific class or subclass of T cells selected from the group consisting of helper T cells, suppressor T cells and cytotoxic T cells and modulates T cell activity, wherein when said T cell specific binding ligand which binds to a specific class or subclass of T cells is derived from an MHC molecule, such consists of the non-polymorphic region of the MHC molecule; and another of said T cell specific binding ligands is an antigenic peptide associated with disease or a causative agent of disease, or an epitope thereof, and wherein said product is about 20 to 100 amino acids in length.
Oligonucleotides Containing N-Methyl Thiolated Bases Having Antiviral Activity
Assignee: Epoch Pharmaceuticals, Inc.
Patent No.: 5,652,359
Inventors: Meyer, R.B.; Gall, A.A.; Broom, A.D.
Abstract:
Oligonucleotides containing 1-N-alkyl-6-thiopurine, 3-N-alkyl-4-thiopyrimidine and 5-N-alkyl-4-thiopyrazolopyrimidine bases and the corresponding 2'-O-alkylated or allylated nucleotides demonstrate potent antiviral activity in several assays, including the human immunodeficiency virus reverse transcriptase enzyme assay. The oligonucleotides of the invention contain approximately 5 to 99 nucleotide units, and may include, in addition to the above-noted N-alkylated and thiolated heterocyclic bases, the naturally occurring pyrimidine and purine bases.
Claim:
A homooligonucleotide having the formula:
wherein n is an integer between 5 and 99; R1 is C1-C6 alkyl or C2-C6 alkenyl; B is a modified heterocylic base which has the formula (1):
where R2 is C1-C6 alkyl; W1 is H or Y1O(OH)OPÐ; W2 is H or Y2O(OH)OPÐ; Y1 and Y2 independently are H, (CH2)mOH, (CH2)mNH2, a cycloalkyl group of 3 to 30 carbons; a lipophilic group selected from the group consisting of cholesterol, cholic acid, protesterone and estradiol, having an appendant connecting group attached thereto said appendant connecting group being selected from the group consisting of ÐSÐ(CH2)n', ÐNHCOÐ and NHÐ(CH2)n', NHCOÐ and attached to the lipophilic group by the NHCOÐ group, and where m is an integer between 2-25, and n' is 1 to 8.
Halo-Nitro-Isoquinolinone Compounds and Pharmaceutical Compositions Thereof
Assignee: Unassigned or Assigned to Individuals
Patent No.: 5,652,367
Inventors: Kun, E.; Mendeleyev, J.; Kirsten, E.
Abstract:
Unsubstituted or substituted halo nitro and nitroso compounds and their metabolites are potent, selective and non-toxic inhibitors and supressants of cancer growth and viral infections in a mammalian host. The compounds are particularly useful for treatment and supression of tumors and viruses associated with breast cancer, AIDS, herpetic episodes and cytomegaloviral infections. The methods of treatment of tumorigenic and viral diseases by halo nitro and nitroso compounds and their metabolites are described.
Recombinant Varicella-Zoster Virus and Process for Constructing Same
Assignee: Research Foundation for Microbial Diseases of Osaka University
Patent No.: 5,653,976
Inventors: Shiraki, K.; Takahashi, M.
Abstract:
The present invention provides a recombinant varicella-zoster virus prepared by inserting into the viral genome, nucleic acids from hepatitis B virus genome, a genomic DNA of the recombinant varicella-zoster virus, a live vaccine containing the recombinant varicella-zoster virus as an effective ingredient, an antigen derived from the recombinant varicella-zoster virus, and diagnostic agent containing the antigen. The recombinant varicella-zoster virus of the present invention can be utilized as a multivalent vaccine having an excellent immunity effect both on chickenpox and hepatitis B, and the expression products and genomic DNA thereof may be used as a multivalent diagnostic agent.
Claim:
A recombinant varicella-zoster virus live vaccine, comprising the genomic DNA of the Oka varicella vaccine strain and the HpaII fragment of the hepatitis B surface antigen gene, wherein said fragment is inserted into the HincII site of the thymidine kinase gene of said genomic DNA so that the 5'-end of said fragment is linked with the starting codon of said thymidine kinase gene in a correct reading frame, and the hepatitis B surface antigen gene is expressed under sole control of said thymidine kinase gene promoter.
Purified gp120 Composition Retaining Natural Conformation
Assignee: Chiron Corp.
Patent No.: 5,653,985
Inventors: Haigwood, N.L.; Scandella, C.
Abstract:
A method for purifying recombinant HIV gp120 so as to provide a glycopeptide having protein/protein binding properties substantially identical to natural viral HIV gp120, which comprises fractionating a composition containing crude gp120 sequentially using (1) ion exchange chromatography, (2) hydrophobic-interaction chromatography, and (3) size exclusion filtration, collecting at each step a fraction that exhibits specific binding affinity for CD4 peptide. The process is carried out in the absence of any affinity purification steps or any steps (such as reverse-phase HPLC) that use contact protein with organic solvents. The product obtained by this method is a purified, full-length, non-fusion recombinant HIV gp120 glycoprotein having protein/protein-interaction properties substantially identical to gp120 as presented on an HIV virus, including binding affinity for CD4 and binding affinity for at least one antibody capable of neutralizing HIV infectivity.
Attenuated Measles Virus Vaccine, Containing Specific Nucleotide Sequence and a Method for Its Absolute Identification
Assignee: Kitasato Institute
Patent No.: 5,654,136
Inventors: Sasaki, K.; Mori, T.; Makino, S.
Abstract:
A measles vaccine virus AIK-C strain comprises genomic RNA that produces by reverse transcription cDNA having a specific nucleotide sequence indicative of the viral genomic RNA in the seed virus for measles vaccine or measles virus vaccine. The complete sequence of 15,894 nucleotides has been determined.
High Affinity HIV Nucleocapsid Nucleic Acid Ligands
Assignee: NeXstar Pharmaceuticals, Inc.
Patent No.: 5,654,151
Inventors: Allen, P.N.; Gold, L.
Abstract:
Methods are described for the identification and preparation of high-affinity nucleic acid ligands to HIV-1 nucleocapsid. Included in the invention are specific RNA ligands to HIV-1 nucleocapsid identified by the SELEX method. Also included are RNA ligands that inhibit the function of HIV-1 nucleocapsid.
Claim:
A method for identifying nucleic acid ligands to nucleocapsid comprising: a) preparing a candidate mixture of nucleic acids; b) contacting the candidate mixture of nucleic acids with nucleocapsid, wherein nucleic acids having an increased affinity to nucleocapsid relative to the candidate mixture may be partitioned from the remainder of the candidate mixture; c) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; and d) amplifying the increased affinity nucleic acids to yield a mixture of nucleic acids enriched for nucleic acid sequences with relatively higher affinity and specificity for binding to nucleocapsid, whereby nucleic acid ligands of nucleocapsid may be identified.
Herpes Simplex Virus Glycoprotein D Variants
Assignee: Competitive Technologies, Inc.
Patent No.: 5,654,174
Inventors: Cohen, G.H.; Eisenberg, R.J.; Nicola, A.
Abstract:
The present invention provides variant HSV-1 glycoprotein D and HSV-2 glycoprotein D molecules capable of preventing infection of cells by herpes simplex virus types 1 and/or 2. Also provided are novel purified and isolated polynucleotides encoding the variant gD molecules. HSV gD-1 and gD-2 region IV variants or fragments thereof are specifically contemplated by the invention. The presently preferred variant molecule gD-1(delta 290-299t) is the product of recombinant expression in Sf9 cells of a fusion protein including the signal peptide of honeybee melittin and Patton strain HSV-1 gD wherein (1) the Patton strain amino acid residues 290 through 299 of the mature gD-1 protein have been replaced with the amino acid residues arginine, lysine, isoleucine and phenylalanine, and (2) Patton strain amino acid residues 308 through 369 have been replaced with five histidine residues. When expressed in Sf9 cells, cleavage of the melittin signal peptide results in the presence of aspartate and proline residues at the amino terminus of the variant molecule. The amino acid sequence of gD-1(delta 290-299t) is set out in Seq. I.D. No. 2 [sequences not shown] and the preferred DNA sequence encoding gD-1(delta 290-299t) is set out in Seq. I.D. No. 1. Administration of gD variant molecules of the invention to mammalian subjects, especially humans, for the purpose of preventing HSV infection and/or ameliorating pathological sequelae of HSV infection is specifically contemplated.
Oral Immunization by Transgenic Plants
Assignee: Washington University
Patent No.: 5,654,184
Inventors: Curtiss, R.; Cardineau, G.A.
Abstract:
The invention is directed to transgenic plants expressing colonization and/or virulence antigens specified by genes from pathogenic microorganisms. It is also directed to the use of such transgenic plants for oral immunization of humans and other animals to elicit a secretory immune response which inhibits colonization of or invasion by such pathogenic microorganisms through a mucosal surface of humans or other animals.
Claim:
A method of making a composition suitable for eliciting a secretory immune response in a human or other animal, said composition comprising a transgenic plant or transgenic plant tissue obtained from said transgenic plant which comprises and expresses a DNA sequence coding for an antigen or antigenic determinant of a pathogenic microorganism, said antigen or antigenic determinant being capable of eliciting a secretory immune response upon oral administration of said transgenic plant or said transgenic plant tissue, wherein the method comprises the step of mixing said transgenic plant or said transgenic plant tissue with a food substance.
Vectors Expressing Hybrid Viruses, Methods of Use and Novel Assays
Assignee: Dana-Farber Cancer Institute
Patent No.: 5,654,195
Inventors: Sodroski, J.; Haseltine, W.A.; Letvin, N.; Li, J.
Abstract:
A vector which can be used to establish a hybrid SIV/HIV-1 virus is described. This virus can be used to infect an animal such as a monkey to establish an animal model for in vivo testing. This animal model can be used for purposes such as screening for therapeutics, adjuvants and vaccines.
Claim:
A vector comprising a 5' DNA segment and a 3' DNA segment, wherein (a) the 5' DNA segment contains a sufficient number of nucleotides corresponding to an SIV or HIV-2 genome to encode functional SIV or HIV-2 gag protein, pol protein, pro protein, vif protein and vpx protein, and has an SIV or HIV-2 LTR, and, (b) the 3' DNA segment contains a sufficient number of nucleotides corresponding to at least one HIV-1 genome to encode a functional HIV-1 env protein, HIV-1 tat protein, and HIV-1 rev protein and a sufficient number of nucleotides corresponding to an SIV or HIV-2 genome to encode a functional nef protein and has an SIV or HIV-2 LTR, and, (c) the vector contains a sufficient number of nucleotides corresponding to an SIV or HIV-2 genome to encode a functional SIV or HIV-2 vpr protein.
Biologically Active Peptides Having N-Terminal Substitutions
Assignee: Magainin Pharmaceuticals, Inc.
Patent No.: 5,654,274
Inventor: Kari, U.P.
Claim:
A composition for inhibiting growth of a target cell, virus, or virally-infected cell, comprising (a) an N-terminal substituted peptide having the formula:
wherein X is a biologically active peptide, said peptide being an ion channel-forming peptide, wherein X includes the following basic structure X50: R41-R42-R42-R41-R42-R42-R41-R41-R42-R41-R41, wherein R41 is hydrophobic amino acid, and R42 is basic hydrophilic or neutral hydrophilic amino acid; T is a lipophilic moiety, wherein if T is
R is hydrocarbon having at least 2 carbon atoms; and W is T or hydrogen; and (b) an acceptable pharmaceutical carrier, wherein said peptide is present in an amount effective to inhibit growth of the target cell, virus, or virally-infected cell.
Polysubstituted Benzimidazoles as Antiviral Agents
Assignee: University of Michigan
Patent No.: 5,654,283
Inventors: Townsend, L.B.; Drach, J.C.
Abstract:
This invention relates to novel polysubstituted benzimidazoles and compositions and their use in the treatment of viral infections. The polysubstituted benzimidazoles and compositions of the present invention exhibit antiviral properties against viruses of the herpes family, particularly human cytomegalovirus (HCMV) and herpes simplex viruses (HSV).
Claim:
An antiviral compound selected from the group consisting of compounds having the following formula, and pharmaceutically acceptable salts thereof:
wherein: R1 is H, R2 is Cl, R3 is Cl, R4 is H, R5 is Br and R6 is H (denoted compound 7 in the text); R1 is H, R2 is Cl, and R3 is F, R4 is H, R5 is Cl and R6 is H (denoted compound 12c in the text); R1 is H, R2 is I, R3 is NO2, R4 is H, R5 is Cl and R6 is H (denoted compound 26 in the text); R1 is Cl, R2 is H, R2 is Cl, R4 is H, R5 is Cl and R6 is H (denoted compound 32 in the text); R1 is H; R2 is I, R3 is I, R4 is H, R5 is Cl and R6 is H (denoted compound 41 in the text); and R1 is Cl, R2 is H, R3 is CF3, R4 is H, R5 is Cl and R6 is H (denoted compound 41c in the text).
Disaccharide Derivative
Assignee: Suntory Ltd.
Patent No.: 5,654,289
Inventors: Kodama, T.; Saitoh, M.; Ogawa, T.
Abstract:
A novel disaccharide derivative represented by the following formula [see claim], which is the compound of the present invention, its stereoisomers and salts and a medicinal composition comprising the same as an active ingredient. The compound of the present invention has various biological activities, for example, potent mitogenic activity, adjuvant activity, polyclonal B cell activating (nonspecific protective) activity, natural killer activity, antitumor activity, antiviral activity, etc., but little harmful effects, for example, function of inducing the production of so-called inflammatory cytokines such as tumor necrosis factor (TNF) and IL-1 from macrophages. Therefore it is highly useful as an immunopotentiator, an antitumor agent, an antiviral agent as well as an agent for preventing and treating sepsis, chronic rheumatoid arthritis, etc. without showing any harmful effects such as lethal toxicity or pyrogenicity as observed in the conventional lipid A and derivatives thereof.
Claim:
A novel disaccharide derivative; (1) having, as the basic skeleton, a glucosamine beta-(1-6)disaccharide structure, to which a phosphate group is attached to the 1-position via an ester linkage; (2) having 3-hydroxy-15-methylhexadecanoic acid attached to the amino group at the 2-position via an amide linkage; (3) having 3-hexadecanoyl-15-methylhexadecanoic acid attached to the amino group at the 2'-position via an amide linkage; (4) having no phosphate group at the 4'-position; and (5) the hydroxyl groups at the 3-, 3'- and 4'-positions remaining in a free state; or its salt.
Compositions and Methods for Inhibiting Replication of Human Immunodeficiency Virus-1
Assignee: University of California
Patent No.: 5,654,398
Inventors: Frankel, A.; Tan, R.; Hudson, D.
Abstract:
Compositions and methods for identifying compositions which inhibit binding of the Rev protein to the Rev-responsive element in cells infected by HIV-1 are provided. The compositions display or mimic the electronic configuration of a binding domain within the native Rev protein, but are free from those portions responsible for Rev activity and are preferably modified to display enhanced binding affinity to the RRE. Screening methods for identifying polypeptides and other compositions having such enhanced binding affinity are also described.
Claim:
A polypeptide having 30 or fewer amino acids with a stabilized electronic configuration and molecular conformation which binds to the IIB site of Rev-responsive element of HIV-1 with an affinity greater than that of the wild-type REV protein, wherein the alpha-helical conformation of said polypeptide is more stable than that of Rev34-50.
Borna Disease Virus-Specific Protein and Kits
Assignee: Johns Hopkins University
Patent No.: 5,654,401
Inventors: Clements, J.E.; Narayan, O.; Vandewoude, S.; Richt, J.A.
Abstract:
Borna disease virus (BDV) causes a rare neurological disease in horses and sheep. A subtractive cDNA expression library was constructed with poly A-selected RNA from a BDV infected MDCK cell line. A clone (B8) was isolated that specifically hybridizes to RNA isolated from BDV-infected brain tissue and BDV-infected cell lines. This clone hybridizes to four BDV-specific positive strand RNAs and one negative strand RNA in BDV-infected rat brain. Nucleotide sequence analysis of the clone suggests that it represents a full length mRNA which contains several open reading frames. The Borna Disease Virus DNA sequences and proteins encoded by the BDV DNA sequences are provided.
Process of Preparing Michellamine Compounds
Assignee: U.S. Dept. of Health & Human Serv./NIH
Patent No.: 5,654,432
Inventors: Boyd, M.R.; Cardellina, J.H.; Manfredi, K.P.; Blunt, J.W.; Pannell, L.K.; McMahon, J.B.; Gulakowski, R.J.; Cragg, G.M.; Bringmann, G.; Thomas, D.; Jato, J.
Abstract:
The present invention provides new antiviral compounds, i.e., michellamines and derivatives and pharmacologically acceptable salts thereof, methods for isolating such antiviral compounds from a plant species of the genus Ancistrocladus, antiviral compositions containing such antiviral compounds, and methods of using such antiviral compounds for treating patients with viral infections. The antiviral compounds of the present invention inhibit the reproduction and cytopathicity of human acquired immunodeficiency viruses.
Claim:
A method of isolating a compound having the formula:
from Ancistrocladus sp. novum (DT 6889), which comprises: (a) extracting dried plant material with an organic solvent to obtain a crude extract; (b) acid-base partitioning said crude extract to obtain a crude organic base fraction; (c) subjecting said crude organic base fraction to centrifugal partition chromatography; and (d) isolating said michellamines with an amino-bonded phase HPLC column.
Compounds for the Photo Decontamination of Pathogens in Blood
Assignee: Cerus Corp.
Patent No.: 5,654,443
Inventors: Wollowitz; S.; Isaacs; S.T.; Rapoport; H.; Spielmann; H.P.
Abstract:
Psoralen compound compositions are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which yet permit their binding to nucleic acid of pathogens. Reaction conditions that photoactivate these bound psoralens result in covalent crosslinking to nucleic acid, thereby inactivating the pathogen. Higher psoralen binding levels and lower mutagenicity results in safer, more efficient, and reliable inactivation of pathogens. In addition to the psoralen compositions, the invention contemplates inactivating methods using the new psoralens.
Amino Acids and Peptides Having Modified C-Terminals and Modified N-Terminals
Assignee: Magainin Pharmaceuticals Inc.
Patent No.: 5,654,451
Inventor: Kari, U.P.
Abstract:
Compounds which have one of the following structural formulae [see claim; truncated]...are useful as pharmaceuticals for inhibiting the growth of target cells, viruses, or virally-infected cells.
Claim:
A compound having the following structural formula:
wherein AA is an amino acid or a chain of two or more amino acids, excluding the N-terminus and C-terminus from said amino acid or chain of two or more amino acids; R1 is hydrogen or an alkyl group having 1 to 8 carbon atoms; R2 is selected from the group consisting of: (i) an aliphatic hydrocarbon having from 1 to about 20 carbon atoms, and:
wherein R4 is an aliphatic hydrocarbon having 1 to 4 carbon atoms; and R3 is selected from the group consisting of: (i) hydrogen; and
wherein R5 is hydrogen or a nitro group.
Recombinant Raccoon Pox Virus Comprising the DNA Encoding the Nucleocapsid Protein of Feline Infectious Peritonitis Virus
Assignee: American Home Products Corp.
Patent No.: 5,656,275
Inventors: Wasmoen, T.; Chavez, L.; Chu, H.-J.
Abstract:
This invention provides a recombinant raccoon poxvirus that expresses the nucleocapsid and transmembrane proteins of Feline Infectious Peritonitis Virus. The recombinant viruses are useful as vaccines, either alone or in combination with carriers and adjuvants.
Claim:
A vaccine comprising: a recombinant raccoon poxvirus having at least one internal gene comprising a DNA sequence encoding the nucleocapsid (N) protein of Feline Infectious Peritonitis Virus (FIPV), and a pharmaceutically acceptable carrier. The vaccine of claim 3 further comprising inactivated or attenuated viruses selected from the group consisting of feline leukemia virus, feline panleucopenia virus, feline rhinotracheitis virus, feline calicivirus, feline immunodeficiency virus, feline herpesvirus, feline enteric coronavirus, and mixtures thereof.
DNA Sequences Derived from the Genome of the Papillomavirus HPV39, Their Use in In Vitro Diagnosis and for the Production of an Immunogenic Composition
Assignee: Institut Pasteur; Inst. National de la Sante et de la Recherche Medicale (INSERM)
Patent No.: 5,656,423
Inventors: Orth, G.; Volpers, C.; Streeck, R.E.
Abstract:
Specific DNA sequences derived from the genome of papillomavirus HPV 39 are provided. Also provided are hybridization probes, and methods for diagnosing genital neoplasias and for detecting infection by HPV 39.
DNA Sequence for the Unique Sequence Herpes Simplex Virus Type 2-Glycoprotein G Protein and Method of Expressing Said Unique Sequence of HSV-2gG
Assignee: CIBA Corning Diagnostics Corp.
Patent No.: 5,656,457
Inventors: Parkes, D.L.; Coates, S.R.
Abstract:
Disclosed are recombinant, synthetically and otherwise biologically produced novel proteins and polypeptides which are encoded by the DNA sequence for HSV-2 glycoprotein G (gG) or fragments of said gG sequence, particularly by the unique sequence for gG or portions of said unique sequence. The unique sequence proteins and polypeptides are serologically active, can be produced easily and safely at low cost, are useful as diagnostic reagents for HSV-2 and as vaccines against HSV-2. Further disclosed are serological assays based on such unique sequence gG proteins and polypeptides that diagnose the presence of HSV-2 specific antibodies and can differentiate between HSV-2 and herpes simplex virus type 1 (HSV-1) specific antibodies. Such assays are useful to diagnose genital infections, to detect for exposure to HSV-2 and to screen pregnant women to protect newborns from neonatal HSV-2 infection. Also disclosed are antibodies to such gG proteins and polypeptides which are useful therapeutically, diagnostically and for affinity purification. Further disclosed are purified and isolated DNA molecules which can be used as probes specific for HSV-2 DNA.
Use of Lymphocytes Transformed with Herpesvirus Saimiri in a Process for Replicating Viruses of the HIV Type which Cause Immune Deficiency
Assignee: Behringwerke AG
Patent No.: 5,656,475
Inventors: Nick, S.; Fickenscher, H.; Biesinger-Zwosta, B.; Jahn, G.; Fleckenstein, B.
Claim:
A process for replicating viruses of the HIV type which cause immune deficiency, wherein the viruses are replicated with the aid of lymphocytes which have been transformed with herpesvirus saimiri.
Compounds which Inhibit HIV Replication
Assignee: Duke University
Patent No.: 5,656,480
Inventors: Wild, C.T.; Matthews, T.J.; Bolognesi, D.P.
Abstract:
This invention relates to human immunodeficiency virus (HIV) protein fragments which have antiviral activity, and particularly relates to HIV peptides derived from the HIV transmembrane glycoprotein (gp41) which inhibit HIV-induced cell-cell fusion. This invention further relates to methods for the inhibition of enveloped viral infection, and to methods that modulate biochemical processes which involve coiled coil peptide interactions.
Papillomavirus E2 Trans-Activation Repressors
Assignee: Biogen, Inc.; New England Medical Center Hospitals, Inc.
Patent No.: 5,656,599
Inventors: Androphy, E.J.; Barsoum, J.G.
Abstract:
This invention relates to E2 trans-activation repressors which interfere with normal functioning of the native full-length E2 transcriptional activation protein of the papillomavirus. Native full-length E2 trans-activation protein activates transcription of papillomavirus only through binding to DNA, and it binds to DNA only in the form of a pre-formed homodimerÑa pair of identical polypeptide subunits held together by non-covalent interactions. The E2 trans-activation repressors of this invention are proteins, polypeptides or other molecules that dimerize with full-length native E2 polypeptides to form inactive heterodimers, thus interfering with the formation of active homodimers comprising full-length native E2 polypeptides, thereby repressing papillomavirus transcription and replication. The E2 trans-activation repressors of this invention are advantageously used in the treatment of papillomavirus infections and their associated diseases.
Pharmaceutical Composition for Inhibiting the Growth of Cancers and Viruses in Mammals
Assignee: Procter & Gamble Co.
Patent No.: 5,656,615
Inventor: Camden, J.B.
Abstract:
This invention is a pharmaceutical composition that inhibits the growth of cancers and tumors in mammals, particularly in human and warm blooded animals. The composition contains a 10:1 to 1:10 mixture of (1) N-chlorophenyl carbamates and N-chlorophenylthiocarbamates and (2) N-phosphonoglycine derivatives which are systemic herbicides. This composition can also be used to treat viral infections.
Derivatives of Purine, Process for Their Preparation and a Pharmaceutical Preparation
Assignee: Medivir AB
Patent No.: 5,656,617
Inventors: Lindborg, B.G.; Datema, R.; Johansson, K.N.; …berg, B.F.
Abstract:
Antivirally active compounds of formula I [see claim; truncated]... processes for preparation of said compounds, a pharmaceutical composition comprising said compounds, methods for treatments of virus infections as well as use of compounds of formula (I) without the proviso for the manufacture of a medicament for treatment of AIDS.
Claim:
A compound of the formula:
wherein: R1 is hydrogen, hydroxy, mercapto or amino; R2 is amino; R3 and R4 are independently selected from:
amino, or R3 together with R4 is:
wherein M is hydrogen or a pharmaceutically acceptable counterion; and n is 1 or 2, and pharmaceutically acceptable salts thereof.
Use of L-Acetylcarnitine for the Treatment of AIDS
Assignee: ZW Biomedical Research AG
Patent No.: 5,656,628
Inventors: Weil, R.; Scandurra, L.
Abstract:
This invention relates to the use of L-acylcarnitine for the preparation of a drug and a technique for relieving the disease symptoms appearing in AIDS by administering an L-acylcarnitine. The invention furthermore relates to a drug for this purpose, characterized in content by L-acylcarnitine as active principle. The preferred L-acylcarnitine is L-acetylcarnitine.
Polypeptides of Feline T-Cell Lymphotrophic Lentivirus
Assignee: IDEXX Laboratories, Inc.
Patent No.: 5,656,732
Inventors: Andersen, P.R.; OÕConnor, T.P.; Tonelli, Q.J.
Abstract:
Purified polypeptides of Feline Immunodeficiency Virus (FIV) are disclosed. The polypeptides of the invention include p10, p15, p26, gp40, gp100 and gp130.
Claim:
Purified and isolated FIV gp40. Purified and isolated FIV gp100. Purified and isolated FIV gp130.
Anti-HIV-1 Neutralizing Antibodies
Assignee: Verigen, Inc.
Patent No.: 5,658,569
Inventors: Osther, K.B.; Kellermann, G.H.
Abstract:
The disclosure relates to antibodies reactive with HIV-1 antigens and the use of such antibodies in vaccine preparations, immunotherapeutic preparations and assays for HIV-1.
Claim:
Isolated polyclonal anti-gp48 antibodies immunologically reactive with gp48 antigen.
Infectious Bursal Disease Virus Recombinant Poxvirus Vaccine
Assignee: Virogenetics Corp.
Patent No.: 5,658,572
Inventors: Paoletti, E.; Taylor, J.
Abstract:
What is described is a recombinant poxvirus, such as fowlpox virus, containing foreign DNA from infectious bursal disease virus. What is also described is a vaccine containing the recombinant poxvirus for inducing an immunological response in a host animal inoculated with the vaccine.
Claim:
A recombinant avipox virus containing in a nonessential region of the avipox virus genome, DNA from infectious bursal disease virus which codes for and is expressed as infectious bursal disease virus structural polyprotein VP2, VP3, VP4, wherein the recombinant avipox virus induces an immunological response in a host animal inoculated therewith.
Process for the Sterilization of Biological Compositions Using UVA1 Irradiation
Assignee: New York Blood Center, Inc.
Patent No.: 5,658,722
Inventors: Margolis-Nunno, H.; Ben-Hur, E.; Horowitz, B.
Abstract:
An improvement in a process for inactivating extracellular and intracellular viruses in a platelet containing composition is presented. The improvement in the process comprises adding a sensitizer to the platelet containing composition and irradiating the composition containing the sensitizer with UVA1 in the absence of UVA2 for a period of time sufficient to inactivate the viruses while retaining the functionality of the platelet containing composition. A quencher or mixture of quenchers of type I and type II photodynamic reactions may be advantageously added to the composition prior to irradiation.
Claim:
In a process for treating an extracorporeal blood platelet-containing composition to inactivate an extracellular or intracellular virus that may be present therein, said process comprising the steps of adding an irradiation sensitizer to said composition and then subjecting the resultant composition to a virucidally effective amount of irradiation, wherein the improvement comprises utilizing as the source of said irradiation a source that emits a virucidally effective amount of UVA1 irradiation in the absence of UVA2 irradiation.
Method of Adsorbing Viruses from Fluid Compositions
Assignee: Ligochem, Inc.
Patent No.: 5,658,779
Inventors: Krupey, J.; Smith, A.D.; Arnold, E.; Donnelly, R.
Abstract:
A method of adsorbing from a solution comprising a biological sample viruses which retain their viability and infectivity. The method comprises adjusting the pH of said solution to pH 6.0 to 8.0; adding an effective amount of a water insoluble cross-linked polycarboxylic acid polymer (ÒWCPPÓ) into said solution in a volume:volume ratio of WCPP to solution of 100:1 to 1:10,000 to form a WCPP-solution mixture; incubating said WCPP-solution mixture for a time sufficient to immobilize said viruses on said WCPP forming a WCPP-virus matrix; and separating said matrix from said solution. This novel method is suitable for removing, purifying, recovering and analyzing viable viruses as well as viral components such as viral proteins and nucleic acids.
Adeno-Associated Virus Materials and Methods
Assignee: ChildrenÕs Hospital, Inc.
Patent No.: 5,658,785
Inventor: Johnson, P.R.
Abstract:
The present invention provides adeno-associated virus (AAV) materials and methods which are useful for DNA delivery to cells. More particularly, the invention provides recombinant AAV (rAAV) genomes, methods for packaging rAAV genomes, stable host cell lines producing rAAV and methods for delivering genes of interest to cells utilizing the rAAV. Particularly disclosed are rAAV useful in generating immunity to human immunodeficiency virus-1 and in therapeutic gene delivery for treatment of neurological disorders.